

产品名称: **LJI308**

产品别名: **LJI308**

**生物活性:**

生物活性:						
Description		LJI308 is a new and potent pan-RSK inhibitor, with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. IC50 value: 6/4/13 nM Target: RSK1/2/3 in vitro: LJI308 efficiently inhibits RSK activity. LJI308 inhibits S6K1 with an IC50 of 0.8 μM, representing a 200-fold lower inhibition than that of RSK2. LJI308 inhibits MEK4 less than 50% at 10 μMand HIP kinase 1 less than 50% at 1 μM. [1] LJI308 inhibits the growth and survival of TNBC. LJI308 also suppresses the growth of HTRY-LT cells in 3-dimensional soft agar cultures. LJI308 is one of the first potent and effective targeted therapies for TNBC that, unlike currently utilized drugs, exhibits efficacy in eliminating the CSC population. [2]				
Solvent&Solubility		In Vitro:				
		DMSO : 25 mg/mL (67.86 mM; Need ultrasonic)				
			Solvent / Mass / Concentration	1 mg	5 mg	10 mg
		Preparing Stock Solutions	1 mM	2.7146 mL	13.5729 mL	27.1459 mL
		5 mM	0.5429 mL	2.7146 mL	5.4292 mL	
	10 mM	0.2715 mL	1.3573 mL	2.7146 mL		
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。						
储备液的保存方式和期限 -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时，请在 6 个月内使用， -20℃ 储存时，请在 1 个月内使用。						
References		[1]. Aronchik I, et al. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers. Mol Cancer Res. 2014 May;12(5):803-12. [2]. Davies AH, et al. Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells. Oncotarget. 2015 Aug 21;6(24):20570-7. [3]. Jain R, et al. Discovery of Potent and Selective RSK Inhibitors as Biological Probes. J Med Chem. 2015 Sep 10;58(17):6766-83.				